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Abstract 
Clinical exome sequencing (CES) is an established method for genetic diagnosis that is 
commonly used in clinical practices. Studies examining the CES experience for families have 
primarily been non-Latino white participants who speak English. To begin to address how these 
experiences may differ in other populations, we conducted in-depth semi-structured interviews. 
Interviews were completed with 22 Latino parents (14 in English; 8 in Spanish) of children who 
had pediatric CES at Columbia University Medical Center and received results within three to 20 
months of the interview. We also measured acculturation with a standardized scale. Similar to 
prior studies, parents reported varied emotional reactions to their child’s results. Parents largely 
understood their child’s CES results though were not always able to correctly recall recurrence 
risk. The majority of participants reported feelings of anxiety while waiting for CES results. 
Some parents, particularly those not fluent in English with lower acculturation scores, reported 
language barriers to their understanding of the testing and their child’s care. Faith appeared to be 
a positive coping mechanism that was more frequently reported by participants with lower 
acculturation scores. Our findings are consistent with many of the previous studies of parental 
experience of CES but highlight some key findings that warrant further study and potentially 
inform practice. Larger studies should explore potential associations between acculturation and 
parental understanding or emotional response to results. The minimal language barriers reported 
by Spanish-speaking patients reiterates the importance of a Spanish-speaking provider, when 
possible, and bilingual resources. 
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Introduction  
Clinical exome sequencing (CES) is an established method for genetic diagnosis. 
Implementation of CES as a first or second tier test provides an earlier diagnosis, eliminates the 
cost of traditional testing, and increases the diagnostic yield compared to the standard of care 
(Valencia et al. 2015; Kuperberg et al., 2016; Nolan & Carlson, 2016; Vissers et al., 2017). 
Research to date has demonstrated mixed motivations for obtaining CES, including a 
sense of duty, lack of other options, hope for a diagnosis and the potential for it to guide care and 
treatment (Rosell et al., 2016; Wynn et al., 2018). Many parents report feeling that any 
information at all could improve their quality of life and sense of empowerment (Clift et al., 
2015; Wynn et al., 2018), though previous failed attempts at diagnosis can reduce expectations 
of a diagnosis for parents of children getting CES (Rosell et al., 2016). While a hope for a 
diagnosis was often reported as motivation for testing, parents also feared receiving a diagnosis 
that indicated a shortened lifespan, and implications for their insurance (Rosell et al., 2016, Clift 
et al., 2015).  
 Similar to motivations for testing, reactions to test results are often mixed. Parents felt 
frustrated and sometimes depressed by their CES results (Rosell et al., 2016, Wynn et al., 2018). 
Parents who received a definitive diagnosis for their child experienced relief and appreciation, 
while others experienced a loss of hope by the lack of therapeutic options or isolation by the 
rarity of the diagnosis. Parents who received a possible diagnosis mostly experienced 
hopefulness as they continued to search for a diagnosis, or acceptance at not receiving a 
definitive diagnosis. However, those who received no diagnosis either experienced relief that 
nothing was found, or concern and disappointment as they still sought a reason for their child’s 
symptoms (Krabbenborg et al 2016; Rosell et al., 2016).  
 Parental reaction may also have effects on comprehension of genetic information. In 
instances where the emotional impact is high, parents are less likely to process information 
which can result in a feeling of being overwhelmed. Parental experiences are perceived as 
positive when a dialogue is present between the geneticist and the parent without excessive 
jargon, emotional support is provided, and there is inclusion of medical management suggestions 
(Ashtiani, Makela, Carrion, & Austin, 2014; Browner, Preloran, Casado, Bass, & Walker, 2003; 
Walser et al., 2017).   
With adequate pre-test counseling, parents have been able to accurately explain their 
results and explain the limitations of the CES (Rosell et al., 2016). Parents often request variants 
of uncertain significance (VUS) returned, although there may be confusion about their 
significance (Rosell et al., 2016, Wynn et al., 2018). In terms of secondary findings, parents may 
be willing to learn about them because they believe it may help them contribute to research and it 
may inform decisions about medical management (Clift et al., 2015).  
A study by Wynn et al. found that most parents were able to correctly interpret their 
child’s CES results, and most discrepancies were due to the clinician’s reinterpretation of the 
laboratory report or the return of negative or uncertain results. Timing of testing also impacted 
parental perception, with a lower positive impact associated with increasing age of the child. The 
overall experience was perceived as positive in parents who interpreted the CES results as 
positive. However, one major limitation noted in this study was that most of the participants 
identified as white, non-Latino (2018).  
 The ethical principle of justice in research dictates that all groups of people are invited to 
participate in research. The US population of Latinos is about 17.8% and is projected to increase 
to 28.6% by 2060 (United State Census Bureau, 2017). Despite this, most research on genetic 
disease susceptibility has been done on non-Latino white individuals (Kinney, Gammon, 
Coxworth, Simonsen, & Arce-Laretta, 2010; Wynn et al., 2018).  Members of minority groups 
are also less aware of genetic testing as compared to Caucasians (Hann et al., 2017). 
The Latino population remains underrepresented in genetic research. Language barriers, 
discrimination, low numeracy and literacy, higher rates of being uninsured, lower household 
incomes, and a higher rate of poverty are some of the barriers to implementing genetics into their 
healthcare (Kamara, Weil, Youngblom, Guerra, & Joseph, 2018).  
Ponce et al. (2006) found that English language skills correlated with better health 
outcomes even when race, age, and income are controlled for. Less proficiency in English 
corresponds with lower health literacy and fewer regular visits to the doctors (Bruce et al., 2014; 
Kamara et al., 2018). In addition, physicians view non-English communication as a barrier to 
informed consent or interest in medical care (Bruce et al., 2014). Patients required to assess 
themselves in a language they are not fluent in report themselves as more unhappy, less 
confident, and even less intelligent in the subject matter (Wallin & Ahlström, 2006). Research 
into the attitudes and beliefs of Spanish-speaking people is important to developing public 
awareness among these people (Kinney et al., 2010). 
 Healthcare disparities can alter disease course in minorities. Breast cancer is detected at a 
later stage in Latina women, even while controlling for education, socioeconomic status, and 
detection method (Lantz et al., 2006). This discrepancy is reduced when controlling for detection 
method, but only in Caucasian and African American women and not Latinas, suggesting that 
cultural differences unique to Latinas may outweigh racial differences (Lantz et al., 2006). 
 When communicating genetic testing results, Latino patients request that the information 
be disclosed slowly and without technical jargon (Browner et al., 2003; Kamara et al., 2018). 
Better outcomes have been demonstrated for patients who speak English when receiving a 
genetic diagnosis (Krabbenborg et al., 2016). In addition, people coming from a lower 
socioeconomic status (SES) have been shown to be accustomed to addressing immediate health 
concerns and less concerned with planning for future events (Kamara et al., 2018). Latinos are 
sometimes used to being given a much more paternalistic treatment by their doctors and may see 
non-directiveness as indication that something is not important (Browner et al., 2003; Kamara et 
al., 2018; Vadaparampil et al., 2010).  
 Not only can there be communication barriers between providers and the Latino 
population, but access to genetic testing may be limited as well.  Fewer genetic tests are ordered 
and fewer referrals to genetic counseling are made by physicians who serve mostly minorities 
(Shields, Burke, & Levy, 2008). This discrepancy may be related to competing health priorities 
among minorities (who tend to present to care sicker and receive more emergency care), the 
lower level of board certification of minority-serving physicians, or simply minority patients 
being offered less genetic testing (Shields et al., 2008). Other barriers to genetic testing among 
Latinos are similar to reported barriers to general healthcare including logistical concerns - 
insurance status and competing life concerns, such as childcare and other life responsibilities 
(Sussner, Jandorf, Thompson, & Valdimarsdottir, 2013). The issue of “competing life concern” 
was reported by Sussner as the biggest barrier to Latinas pursuing testing, and made them less 
likely to undergo BRCA1/2 testing (2013). 
 In addition to considering how to tailor information to the Latino population, their 
perception of genetic testing could influence how information is received. Not much is known 
about the psychosocial and emotional reactions to genetic testing that are unique to Latinos 
(Hickey et al., 2014; Kinney et al., 2010). Male Latinos tend to experience anxiety around 
personal peril and employment-related barriers, while females tend to be concerned with heredity 
implications of genetic diseases, such as how it would affect their children and pain associated 
with genetic testing (Hamilton et al., 2016, Hickey et al., 2014). Latinos perceive the risk of 
emotional harm from genetic testing to be higher than Caucasians do, though both ethnicities 
have relatively low levels of perceived risk of harm (Palmer et al., 2008). Fatalistic attitudes can 
prevent Latinos from recommending testing to other people (Vadaparampil et al., 2010). 
 Latinos have been shown to want genetic testing for the purpose of helping affected 
individuals, their families, and other families, as well as to learn recurrence risk or to explain 
family history, whereas non-Latino Caucasians more frequently reported discovering the 
etiology of a disease as reasons to pursue testing (Palmer et al., 2008). However, a more recent 
study found that there was no significant differences between Latina and non-Latina women in 
perceived benefits or desired counseling topics in a hereditary cancer setting (Gammon et al., 
2011). Studies show Latinos understand the basics of genetic testing and believe that it can 
provide valuable health information and may lead preventative measures; however, language 
barriers are listed as a hindrance to doctor-patient communication and the purpose of genetic 
testing, how it is performed, and the information it provides are less well understood (Hamilton 
et al. 2016). 
 Latina women have misconceptions about BRCA1/2 genetic testing, unawareness of 
familial breast and ovarian cancer, and ignorance about the availability of genetic risk 
assessment. Benefits of genetic testing reported by these women included information for their 
children and future generations (Kinney et al., 2010). 
 In addition, attitudes toward genetic testing in Latinos are often influenced by levels of 
acculturation, or the degree to which an individual from a minority culture has adopted the 
mainstream culture. Latino women with lower acculturation tend to be diagnosed with breast 
cancer at a later stage than their more acculturate peers (Lanz et al., 2006). Knowledge of genetic 
testing is lower among Latinos than non-Latino whites, but this knowledge gap becomes smaller 
with increased acculturation (Sussner, Thompson, Valdimarsdottir, Redd, & Jandorf, 2009). As 
acculturation increases, Latinos report fewer barriers, more perceived benefits, and more 
favorable attitude towards genetic testing (Sussner et al., 2009). 
         One social barrier that cultural sensitivity can ease is the language barrier. Some medical 
terms in English may not have an equivalent in the patient’s language, making it difficult for 
both translators and interpreters. In addition, when translating from one language to another, the 
concept or meaning of the sentence may be altered unintentionally which can skew results in a 
qualitative interview. Interpretation also depends on the skill level of an interpreter and their 
ability to interpret effectively. 
         Despite the recognized effects of a language barrier, this is infrequently addressed in 
qualitative studies. Qualitative interviews have been used in many studies to determine a 
patient’s perception, but few studies have explored the effect of the language barrier. A review of 
40 scientific cross-language qualitative studies found that researchers often do not acknowledge 
language barriers as a possible limitation of their study and do not explore the possibility of it 
affecting the analysis and interpretation of results. In addition, only seven studies pilot tested 
their interview guides in the native language of the participants, and half of the studies did not 
mention the credentials of the interpreter or at which point in the interview the interpreter was 
used (Squires, 2009). 
         This study aims to identify both common and unique themes pertaining to the Latino 
population and their experience of CES results. These themes include, but are not limited to, the 
parental experience of education and consenting, initial reactions to the CES results, their 
decision to have testing, the experience of waiting for and receiving results, and the resources 
received and needed throughout the process. Barriers to their genetic healthcare will also be 
explored. 
         The projected increase in the Latino population within the United States highlights the 
need for minority populations to be significantly represented within healthcare research. This is 
the first study that aims to understand the experience of Latino parents who have had CES on 
their children. The findings from this study can be used to identify barriers to genetic testing in 
Latinos, and more specifically, the challenges associated with genetic testing when involving a 
child with a genetic condition. The results of this study have the potential to improve their 
healthcare in a positive manner by including genetics. 
 
Methods & Materials 
This study was carried out in the Division of Clinical Genetics at Columbia University 
Medical Center (CUMC) in New York City. Interview guides and participant contact materials 
were developed by the authors and translated by bilingual research assistants, and subsequently 
approved by the Columbia University Institutional Review Board. Interview guides assessed 
themes which were identified from the literature as having special relevance to the Latino 
experience with healthcare (access, language barriers, competing life concerns, cost, etc.) as well 
as recognized themes related to receiving genetic test results (impact of testing, sharing results, 
emotional reaction to and understanding of results). 
 
Participants 
The participants for this study were parents of Latino/a pediatric patients who had 
undergone CES at CUMC. Parents were seen in clinic and results session by various members of 
a team of seven genetic counselors, one of whom was Spanish-speaking, and one of five 
geneticists, two of whom were Spanish-speaking. A sample of participants were recruited from a 
database of patients who undergone CES at CUMC in the years 2017 and 2018. Latino 
participants (n=102) were selected for by filtering ethnicity of proband, parents, or grandparents 
as “Hispanic” or “not given,” “Country of Origin” for proband or parents as any Latin American 
country, and “Primary Language” as “English,” “Spanish,” or not listed. Subjects were further 
stratified by those receiving CES results between six to 18 months ago. 
Procedure 
The parents of each participant were contacted by invitation letter in both English and 
Spanish from their treating provider. Invitation letters were followed by up to three invitation 
phone calls made by English-speaking or bilingual RAs. Verbal consent was obtained, and 
interviews were scheduled. Consent forms were sent to enrolled subjects either electronically 
through email link to REDCap (Research Electronic Data Capture) or paper forms through the 
mail. Subjects’ contact history, consents, and interview schedules were tracked in REDCap. 
In-depth, semi-structured interviews were conducted in either in English or Spanish based 
on participant preference. Interviews lasted between 30-60 minutes and were conducted by 
phone by one of two genetic counselors (JW, CK) and attended by genetic counseling interns 
(RS, DL) or a bilingual research assistant (KR). Data collection continued until saturation and all 
interviews were audiotaped. English interviews were transcribed verbatim by a private 
transcription service. Spanish interviews were first transcribed and then translated by bilingual 
Latina research assistants KR or AE. To improve reliability, translation was completed first by 
one RA and then selected quotes were reverse translated (translated back into Spanish) by the 
second RA.  
After each interview, subjects were sent an 8-question survey designed to assess 
acculturation. six questions were from Marin’s Short Acculturation Scale for Hispanics (SASH), 
addressing language use and preferences, and was used as a measure of acculturation. Two 
additional questions were the authors’ own and regarded language use with healthcare providers 
and at work. Responses were on a 5-point Likert scale of “only Spanish” to “only English,” with 
higher scores indicating greater levels of acculturation. Subjects were sent a $25 Amazon gift 
card to compensate them for their time. 
Data Analysis 
Transcripts were uploaded and coded in NVivo software (QSR International Inc., 
Burlington, MA, USA) in a three-stage process by three researchers. Participant narratives were 
reviewed using inductive thematic text analysis, a process of transcript review, interpretation, 
and consensus discussions. Transcripts were coded by researchers JW, RS, and DL on a rotating 
schedule. Primary coding was performed by the assigned researcher for the designated transcript. 
After completion, another researcher was assigned to secondary coding. After secondary coding, 
the final researcher performed tertiary coding. Methodological and analytical documentation 
included the identification of key phrases, similar experiences, common themes, and 
documentation of the subject reaction to the CES experience. All three researchers completed an 




In total, 22 parents were interviewed. Of those parents, 4.5% (N=1) were male and 95.5% 
(N=21), were female, ranging in age from 24 to 53 years old at the time of the interview with an 
average age of 36. Most parents completed high school (86.4%, N=19) and some had a college 
degree (22.7%, N=5). Sixty-eight percent (n=15) of parents were employed full-time or part-
time, while 32% (n=7) were unemployed. Sixty-four percent (n=14) of parents were married and 
36% (n=8) were single. Fourteen parents elected to be interviewed in English and eight in 
Spanish. Besides one father, all of the participants were the mother of the child tested. All 
parents spoke some Spanish and the majority (86.4%) (n=19) identified Spanish at their primary 
language or both Spanish and English as their primary languages. Four (18.2%) parents reported 
they spoke no English. A minority (13.6%, n=3) of parents reported English as their single first 
language. 
Parents had acculturation scores between 4.25 and 1.00. Ten (45.5%) of parents had a 
low acculturation score, classified by a score of 2.99 and below. Twelve (54.5%) parents had a 
high acculturation, classified by a score of 3.0 or above. Low-acculturated parents had an 
average acculturation score of 1.72, while high-acculturated parents had an average score of 
3.41. Of the low-acculturated parents, five held their genetics appointment in Spanish with a 
Spanish-speaking provider, two spoke Spanish and used a translator, and three spoke in English. 
Nine of the 10 low acculturated parents spoke Spanish in the interview for this study. Of the 
high-acculturated parents, 10 spoke English during their genetics appointment and two spoke in 
Spanish with the providers. All 12 high acculturated parents spoke English in our interviews 
(Table 1). 
The average age of the children was 8.4 years old, and 86.4% were insured through 
Medicaid/Medicare. Ten children were female and 12 were male, ranging in age from 1.5 to 18 
years old at the time of the interview. The most common clinical indications were developmental 
delay (n=8), autism spectrum disorder (n=4), seizures (n=2), and hypotonia (n=2). Children were 
seen in the genetics clinic by one of seven genetic counselors and one of five geneticists. 
Thirteen were evaluated by a genetic counselor and/or geneticist who spoke Spanish, the other 
nine either conducted their appointments in English or with the use of a translator. One child had 
exome sequencing through her neurologist. The time from when parents received results to when 
the interview was conducted ranged from 3-21 months with an average time of 13 months (Table 
2). 
All children received CES. Ten children (45.5%) had CES results which did not identify 
any variants, 9 (40.9%) had pathogenic variants identified, and three (13.6%) had VUS 
identified. Two children had negative CES results with a VOUS or pathogenic mutation on 
previous panel or microarray. Of the pathogenic results, four (18.2%) were de novo, three 
(13.6%) could not be determined because one or both parents had not been tested, one (4.5%) 
was an X-linked disease maternally inherited, and one (5%) was an autosomal recessive 
condition with bi-parental inheritance. Nine children (41%) had prior genetic testing before the 
CES was ordered, eight (36%) had CES as a reflex test following an initial negative work up, 
and seven children (32%) had CES concurrently with other testing. In addition to CES, 19 
children (86%) had a karyotype and 21 children (95%) had a microarray, either before or at the 
same time as CES. One child had CES ordered by a neurologist and it is unknown if a karyotype 
or microarray were completed (Table 3). 
 
Understanding of CES  
In general, when asked to recall CES, parents provided a limited description and often 
stated they were not familiar with the terms of exome sequencing. Most parents did not 
distinguish CES from other genetic tests their child had concurrently or in an earlier work up, 
though some recalled a discussion of the comprehensive nature of the testing or the occurrence 
of parental sample collection. Though often unable to provide a detailed description of CES, 
most parents felt comfortable with the information provided to them. 
 
Motivations for CES 
Families expressed an obligation to pursue testing, often expressing that they “had to find 
out” what caused their child’s condition, regardless of treatment options (n=18). However, many 
parents communicated that they had hoped that CES would provide a diagnosis for which there 
was a treatment or cure for their child’s condition (n=6). While many parents expressed hope that 
a genetic cause could be determined, several also hoped that a cause would not be found. Some 
had ambivalent feelings about what they were hoping for. 
A few also indicated the potential to provide information about the risk for other children 
or to guide reproductive risk for themselves or their children as a motivation to have testing 
(n=3). Several participants (n=3) were interested in the potential to learn about secondary results. 
Many parents (n=14) also explained the testing with regards to how it would inform them of 
inheritance, such as which side of the family the condition came from. Eleven parents described 
the purpose of testing as partially to learn which parent had passed on the genes causing the 
condition. Sometimes the question of inheritance was tied to feelings of guilt or fault. 
 
Waiting for Results 
 Waiting for the results was frequently considered to be the most difficult part of the entire 
CES process. When commenting about the amount of time expected for the results to arrive, 
most patients remembered being told to wait three to four months. The only mother who 
repeatedly contacted the hospital asking for her results did so at one and a half months, far earlier 
than most others expected their results, and may have not understood the expected turnaround 
time.  
 
Experience with genetics and how results were received  
Parents generally felt their experience in genetics was positive. With few exceptions, they 
felt comfortable with their providers and felt their questions were answered. Five parents 
reported feeling nervous or overwhelmed at various points in the testing process.  
Some (n=11) recalled receiving the results first by phone, some recalled receiving them 
through an in-person visit, and a few thought they learned the results in a letter. One could not 
recall how they first learned the results. Three parents stated they thought receiving results by 
phone was the best way, and three thought the results would have been better delivered in 
person. Most were satisfied with how they received the results or agreed that there was no 
perfect way. Two parents did not recall ever receiving the full results.  
 
Understanding of and Reaction to Results 
Parents had various reactions to the results, reacting both negatively (sadness, surprise, 
mistrust, disappointment) or positively (hopeful, satisfied, or relieved). There was no noticeable 
difference between parental emotional reaction and their acculturation levels. While some 
parents expressed an initial disbelief in results, most expressed a trust in the results and the 
prognosis. Some parents expressed the permanence of the results, though others, both with 
negative and positive results, felt the results may change and may warrant testing in the future as 
technology advances. 
 
Positive Results (N=9) 
Interpretation 
Almost all parents of children who had a pathogenic variant understood this to be the 
cause of their child’s condition (n=8). Two parents with de novo results were able to explain the 
genetic cause did not come from them but were unsure about recurrence risk and had decided to 
forgo having additional children due to the perceived risk of recurrence. Three of the parents 
were able to name the condition of the diagnosis provided by the test. Most parents had already 
been convinced there was a condition present in their child before the CES, and that the genetics 
confirmed the condition’s presence. 
 
Reaction 
Emotional reactions to positive results were mixed.  Parents of children who received 
positive results often expressed strong negative emotions, such as being shocked, devastated, 
unsatisfied, in disbelief, or sad (n=5, 62%).  One parent reported that his wife doubted the 
genetic etiology and believed vaccines were responsible for the child’s condition. A mother had 
initially been told the results were negative and was in denial when she learned about the 
diagnosis. 
One parent who reported only a modest emotional reaction felt this was related to already 
being aware that her child had a serious condition, and the results did not change this. Three 
parents with positive results expressed hope that the results could lead to some treatment, while 
two parents with de novo positive results expressed relief to learn they had not caused the 
condition. One mother of a child with a de novo muscular dystrophy shared how the results 
helped her to stop blaming herself. 
 
VUS Results (N=3) 
Interpretation 
One parent had a child with a de novo VUS but interpreted the result as negative. She 
reported wanting more information about why CES was performed. Another mother had a child 
with a paternally inherited VUS and understood the uncertainty of the result, the inheritance, and 
the recurrence risk. The mother of the child with the maternally inherited mitochondrial VUS 
was confused about the result and thought further genetic studies were needed.  
  
Reaction 
Patients with VUS results reacted in a variety of ways, from confusion to unconcern. The 
parent of the child with the de novo VUS reported being happy that there was nothing found but 
was confused about why CES was performed and what clinicians expected the result to be. 
Feelings of relief were expressed by the parent of the child with the paternally inherited VUS. 
The mother of the child with the maternally inherited mitochondrial VUS was concerned about 
inheritance and was fearful of a hereditary condition. 
 
Negative Results (N=10) 
Interpretation 
Some parents (n=3) who received a negative CES result for their child seemed to 
understand there was still the potential for a genetic diagnosis despite negative results. Two 
participants expressed a wish for future treatments or testing options. Many parents (n=4) saw 
CES as definitive and believed failure to find a variant meant that the child’s condition was not 
genetic and understood negative results to have eliminated a potential genetic diagnosis. Two 
parents had negative CES results but VUS on an epilepsy panel and did not distinguish between 
the two tests. The parent whose child had a negative CES result but a de novo pathogenic 
deletion on microarray also did not differentiate between the two tests. 
 
Reaction 
Parents who received negative results and felt the results ruled out a diagnosis expressed 
happiness and relief (n=5). Two parents reported being unconcerned about the results due to the 
distractions of caring for their families, one of whom never received the results. Other parents 
with negative results were disappointed to not have an answer (n=3), though two of these parents 
also felt glad the process had been done. One parent with a negative result was unsure if doing 
the test was the right thing for her. 
 
Timing of CES  
Most parents (69%) would have liked to have had the testing done sooner, and no parents 
wished for testing to be done later. Of the parents with pathogenic results who were asked if they 
desired to have testing done sooner, all agreed. For parents who had negative or uncertain results 
many were content with the timing of the test (67%), though some (n=2) would have liked to 
have the testing done earlier.  
 
Impact of CES  
Regardless of the emotional impact of learning the results, almost all parents stated that 
they did not regret doing the test or learning the results, and would do the test again. Relatively 
few sought advice from others before undergoing CES, and none had doubts about the testing 
process.  
Most parents reported no significant impact on their lives regarding insurance, jobs, or 
relationships, but genetic testing has made them more cautious for their other children, has 
caused minor lifestyle changes, and has improved some of their medical interventions. Six 
parents mentioned that there were no negative effects of the testing (2 negative, three VUS, one 
positive). Eight parents mentioned that the tests did not affect their child’s care in any way, five 
of them from the positive result group. Eight parents mentioned the results affected their 
reproductive decisions or feelings about recurrence risk, most (n=5) had positive results. Five 
parents were reassured there was little chance of recurrence, and one said she was considering 
her previous decision to forgo reproduction. Another parent with a positive result said the result 
allowed them to be prepared for a second affected child. A parent with a negative result was 
uncertain of the implications of the test.  
Three parents with positive results and one with a VUS mentioned access to a trial 
treatment or some improvement in the care as a result of the genetic test. Three parents (one 
VUS, two positive) mentioned considering a trial but not seeing improvements or not joining the 
trial.  One parent with a positive result explained they had undergone much personal growth 
since the diagnosis. Another discussed being more cautious with her current child.  
 
Sharing CES Results 
All parents chose to share their child’s CES results with some family members, such as 
their other children, their parents, grandparents, or their siblings. Some parents stated they had a 
family meeting, while others reported they had family members who constantly checked in with 
them about their child’s health. One mother of a child with a de novo muscular dystrophy 
expressed difficulty explaining the condition because of limited information available and the 
misconception that genetic conditions always run in families. 
Others shared that members of their family were not as accepting of the results. The 
father who was interviewed for the study stated that his wife did not accept the test results. She 
believed vaccines were responsible for their child’s autism and planned to pursue direct-to-
consumer testing (DCT) as a second opinion.  Another mother of a child with seizures noted that 
the father had unrealistic expectations that their child would recover or catch up.  
Some parents (n=4) mentioned sharing the results with their friends, while others (n=4) 
reported sharing their child’s diagnosis with the child’s school. Ten parents shared results with 
healthcare providers. There were no overt patterns of sharing based on type of result. Parents 
listed reasons not to share with others due to privacy concerns or their own judgement about who 
they felt needed to know. Some stated that other people who knew about their child’s symptoms 
before CES either did not believe the child’s symptoms were real, thought the symptoms were 
due to the child’s upbringing, or believed in alternative remedies, which is why they chose not to 
share the diagnosis. 
 
Barriers to CES 
The majority of parents did not report physical barriers to their genetics care such as time 
off work, child care, and transportation. However, some parents reflected on the difficulty of 
multiple appointments and taking time off work or finding child care. One mother who received 
car service expressed exasperation with it and eventually purchased a car to attend appointments. 
One parent who reported never learning the results of her child’s testing and not 
following up to inquire about it expressed that it was not her priority given her child’s other 
medical needs. Another parent experienced the death of her grandmother when the results 
became available and she elected to delay the receipt of the results because of this.  
Only two parents had an out of pocket cost of $7,000 and $200, respectively. The 
majority of other parents (n=19) reported no cost of testing. Few recalled having a discussion 
about potential cost at the time the testing was ordered. When asked about whether or not they 
would have pursued the test had there been a cost, two indicated an upper limit of $1,000 and 
$300 respectively, two mentioned they could not have afforded anything, and others (n=3) felt 
they would have found a way regardless of the cost. 
 
Language as a barrier 
Only one participant used a phone translator during their genetics appointment. All other 
parents who conducted the interview in Spanish had Spanish-speaking providers who either 
spoke Spanish with them, chose to speak in English, or used a staff member to translate in-
person.  The Spanish-speaking parent who did not have a provider who spoke Spanish recalled 
that a phone interpreter was used and reported problems with understanding. This parent reported 
wanting more information and not understanding the reason for the test. Three of the parents 
were able to communicate with Spanish-speaking doctors in the session. These parents reported 
no problems with the communication. When asked directly if they were satisfied with the 
information provided in session, only one parent who communicated with the doctor directly in 
Spanish reported being unsatisfied.  
All of our participants spoke at least some Spanish, but several said they preferred to 
speak to providers in English. Three parents had concerns about not knowing as much medical 
terminology in Spanish, and one expressed the preference for English based on the concern that 
Spanish language encounters with providers could cause delay accessing records in case of an 
emergency. Though each of these four parents said they were comfortable in Spanish, they 
scored high on the acculturation scale (average of 3.5). One parent with an acculturation score of 
4.25 reported being perfectly bilingual, and preferred Spanish for the benefit of the people who 
attended the session with her. No parents with a low acculturation score preferred English with 
their providers, and those who voiced a preference for Spanish had an average acculturation 
score of 1.9 (n=5). 
 
Additional Resources  
Additional resources accessed by parents were the use of the internet, their job experience 
in the healthcare field, or parents of other children with the same condition. Overall, Spanish-
speaking, low acculturated parents had the most barriers regarding use of support groups. Only 
one parent, noted to have high acculturation, was actively enrolled in a support group. Three 
parents, all Spanish-speaking with low acculturation, expressed interest in attending a support 
group, and two of these parents stated they were able to find resources in Spanish. One Spanish-
speaking parent stated that she wanted to find resources but was discouraged because of the 
language barrier, while another Spanish-speaking parent stated she would have liked therapy 
with psychologists. However, one parent whose child has Neimann-Pick and stated that the 
online support group provided to her by her child’s neurologist had a representative who could 
communicate with her in Spanish.  
 
Latino experience  
Parents were asked how they felt their ethnicity or culture impacted their experience. 
Many felt that it had little impact and often reflected on how they may differ from other Latinos. 
Others expressed that the larger Latino community may have a different experience because of 
cultural approaches to about health, such as belief in alternative treatments, lower education, 
language barriers, and differences in how information and decisions about health are approached. 
Some used the examples of specific family members and friends and hypothesized that they may 
have relied more on their provider to make the decision to pursue testing, or have more difficulty 
accepting a diagnosis or a prognosis. In terms of acculturation level, very little difference was 
found in the experience of parents based on their acculturation levels.  
 
Religion & Faith  
Some parents occasionally used language relating to “God,” in vernacular such as “thank 
God” or “oh my God” (n=3). Two mothers expressed faith that God could change something in 
relation to their child’s genetic diagnosis while the other mother used her faith to come to terms 
with her son’s diagnosis. All parents who made explicit mentions of faith were slightly above the 
average age of parents in our study, had acculturation scores less than 1.5, and spoke Spanish 
during the CES results session. However, one chose to speak English during their interview. All 
three had children with pathogenic CES results, two of which were de novo and one where 




This study provides insight into the experiences and perceptions of Latina mothers and 
one Latino father of children who have had CES. We examined how these experiences were 
influenced by degree of acculturation. Overall parents reported the experience of having CES 
performed on their children to be positive with few reporting negative experiences. Most 
negative experiences were related to distress upon receiving a diagnosis, waiting for results, and 
difficulties with language.  
Most parents were unable to recall the term “exome sequencing” or describe the test in 
any detail but were satisfied with their understanding and the information provided to them 
regardless. The primary reasons for pursuing testing was a desire to learn everything possible 
about their child’s condition, to obtain advice from providers regarding their child’s diagnosis, 
and a hope for new therapies or treatments.  
Reactions to results were influenced by type of result. Parents receiving positive results 
often expressed feelings of shock or sadness and occasionally hope. Parents who received 
negative results or VUSs often felt relief, confusion, and occasionally disappointment. Most 
participants had good recall of their child’s CES results and an appropriate understanding of the 
results.    
We did not observe a difference in the understanding and interpretation of CES results 
between high acculturated parents and low acculturated parents. This is somewhat inconsistent 
with a previous quantitative study (N=120) of Latina women, which found increased 
acculturation correlating with increased knowledge of genetic testing (Sussner et al., 2009). 
However, we did not specifically ask about prior knowledge of genetic testing.  
Few differences across acculturation levels were observed for barriers to testing, regrets 
around testing experience, or satisfaction with the process of genetic testing. Spanish speaking 
parents were more likely to express difficulty in communicating or understanding the providers, 
and also in finding additional resources during and after the testing process. Similar to a study by 
Rajpal, Munoz, Peshkin, & Graves, few participants felt that their cultural background personally 
influenced their experience but agreed that for other Latino parents it might (2017).  
Our findings of parents’ feelings of guilt about potentially passing down genetic 
conditions contrasts with findings in a recent study of parents in South Africa. A study by 
Gardiner et al (2018) showed that parents of children with hearing loss reported that discovering 
a genetic etiology for the hearing loss would decrease their personal feelings of guilt. Only one 
parent in our study also expressed the idea that discovering a genetic cause would remove their 
feelings of guilt; many more reported apprehensions that the genetic testing would indicate that 
one of the parents were at “fault” genetically for their child’s condition. Gardiner’s study had 
findings which were concordant with ours, such as the perception that a genetic etiology was 
associated with a positive family history. 
 
Lack of diagnostic odyssey and its impact on parental reactions 
The majority of the children in the study had CES as part of their initial genetic 
evaluation or as reflex testing following negative first tier testing. This timing is in contrast with 
other studies of parents of children with CES, where frequently, the child had CES after years of 
evaluation (average of 78 months in the case of Valencia et al. 2015, and 91 months in Rosell et 
al. 2016). This difference may account for some of the differences we observed in our study. 
Many of the parents did not describe the CES testing experience as different than prior or other 
genetic testing their child had or was having. In contrast, other studies have reported parents to 
understand CES accurately as distinct from previous tests, with characteristics such as being 
untargeted (Rosell et al. 2016). 
While waiting for results has been reported as a source of frustration and disappointment 
(Rosell et al. 2016), in our study, parents recalled the waiting period as a source of anxiety and 
anticipation. As CES testing becomes part of second and even first tier testing, this will affect the 
patient/parent experience. Their understanding of the testing may differ as they have had only 
one or two appointments in genetics rather than many over a span of several years. The CES 
process is likely one of the first times where parents have had to wait over a month for a test 
result.  
 
Faith as a coping mechanism 
One theme that emerged was the use of faith and spirituality as a coping mechanism, 
although we did not specifically ask about this during our interviews. Faith has been previously 
explored as having a significant impact on the genetic testing decision-making process in 
individuals who consider themselves religious. For these individuals, there is an added step in the 
decision-making process. Some Latinos may believe genetic testing is punishable by God, while 
others process their understanding of the diagnosis and treatment within the context of their faith 
(Hamilton, et al. 2016; Scully, Banks, Song, & Haq, 2017). Clinicians are less likely to address 
faith and are viewed as disengaged when patients mention their religion (Scully et al., 2017). 
Faith has also been observed as a method of adaptation and resilience in Latinos with cancer. 
This belief system aids in their acceptance of disease and they respond to illness to overcome 
disease (Jurkowski et al. 2010; Hunter-Hernández et al. 2015). 
Similar to other studies in a prenatal setting, we found that several parents, all with lower 
acculturation levels, referenced back to their faith as a coping mechanism, expressing having 
faith in God, waiting for a change from God, or believing their child’s condition was a result of 
God (Thompson et al., 2015; Seth et al., 2011). We also noted that there may be generational 
differences due to the Latinas referencing faith being above the average age of our participants. 
Our cohort did not use their faith as a form of denial about their child’s condition, but rather as a 
coping mechanism or form of acceptance. Recognizing that this need may be more frequent in 
the Latino community could build additional rapport with parents and extract positive reactions 
toward genetic testing in their children.  
Language and Cost Barriers in Latinos  
Our study found few language barriers encountered during the genetics appointment and 
only occasional language barriers during the subsequent search for additional information or 
resources. In fact, of the nine parents who we identified as having expressed misconceptions or 
confusion about the implications of their results (incorrect recurrence understanding, dismissal of 
positive results, believing that negative results signified no possible genetic etiology, confuse 
CES and microarray results, or report not knowing the purpose of the CES), seven of those nine 
were English speakers with high acculturation.  
In past studies language barriers were a reported concern affecting the ability of Latino 
patients to access genetic testing (Kamara et al., 2018; Kinney et al., 2010). Compared to these 
two other studies, our cohort was less foreign born, more English speaking, younger, and more 
educated. The lack of reported language difficulties in our study was most likely due to the 
availability of Spanish-speaking receptionists, genetic counselors, and geneticists in the clinic. 
The solitary Spanish-speaking patient who used a phone interpreter in the counseling session and 
had no Spanish-speaking providers was one of the only parents to report confusion and low 
satisfaction with the information provided. This study illuminates the increased patient 
comprehension that can be provided by a bilingual staff and suggests that always having a 
Spanish-speaking provider on staff and simply asking a patient if they would prefer that Spanish-
speaking provider allows greater understanding by Spanish speaking patients.  
Several of our participants reported difficulties finding additional resources in Spanish, 
such as focus groups or literature on the internet. A similar need for culturally-appropriate 
materials was found among New York Latinos in the cancer genetics setting by Sussner et al. 
(2009), and in a group of Salt Lake area Latinos in Kinney et al. (2010). Our participants 
described using Spanish language resources for providing themselves with helpful information 
but also as being used as a resource for educating extended family members who do not speak 
English.  
Although a minority of bilingual parents preferred using Spanish in the sessions with 
providers for the benefit of Spanish speaking family members also present, almost all of the 
parents who spoke some English expressed a preference to speak with their providers in English. 
This occurred even when the provider spoke Spanish and was attributed to ignorance of medical 
terminology in Spanish or concern that Spanish language encounters with providers could 
become an impediment to medical care.  This indicates that although Spanish may be their first 
language and the language that they are most comfortable using, for those who are bilingual, 
there is a level of discomfort when using Spanish with providers.  
Another barrier that has been explored is the cost of genetic testing. Cost and lack of 
insurance have previously been found to be the most frequent barriers for BRCA1/2 testing in 
Latinos in New York City (Kinney et al., 2010). Our study found almost no concern or even 
discussion of financial costs when testing was ordered among our parents, though our cohort is 
refined for those who already received testing. Five parents either did, or indicated that they 
would have, paid at least $300 for the cost of testing. Only two parents claimed to have been 
unable to afford any cost whatsoever.  
 
Sharing of results   
A study by Velicer et al. found that women who intended to pursue genetic testing were 
twice as likely to have spoken to relatives about the testing (2001). This is consistent with our 
study, where participants who already had testing were generally willing to share their test 
results with providers, family, and friends, with only one parent stating they only shared the 
results with their child’s other parent but no other family members. Other studies have found 
Latinos to be more likely to share medical information or involve family members in the 
decision-making process with a cancer diagnosis (Maly et al., 2006), and family history of 
cancer risk (Corona et al., 2012). 
 
Study Limitations 
There are several limitations to our study. All parents received care at a single institution. 
Parents were cared for by seven GCs and five geneticists, and differences in how each individual 
provider practices may have affected the experiences of the participants. While it is a strength of 
our study that we conducted interviews in both Spanish and English, the Spanish and English 
interviews were conducted by separate individuals and there is potential that information is lost 
in the translation of the Spanish interviews. All quotes from the Spanish language interviews 
were translated back into Spanish by a native speaker to confirm the original translation was 
correct, though there is debate in the literature about whether it is appropriate to analyze 
interviews in two different languages in a single study. Additionally, the Spanish-language 
interviews were conducted by a genetic counselor fluent in Spanish but not a native speaker, 
however a native speaker was present and assisted in any linguistic difficulties. All interviews 
were conducted by phone, and the lack of nonverbal cues may have influenced the interviews 
and therefore our results. The timing of the interview from when the parent had received the 
results varied from three months to one year and nine months. We specifically elected not to 
complete an interview less than three months from receiving results to limit the immediate and 
sometimes transient reactions to results. The timing likely resulted in some recall bias.  
We attempted to capture a diverse sample of Latino/a parents of child with diverse types 
of CES results. This diversity may have limited our ability to capture more subtle themes 
experienced within parents of a certain acculturation or with specific types of results. As all of 
the participants had already undergone CES, our participants are representative of only this sub-
sample. In addition, the term Latino refers to a heterogenous group of peoples. The Latino 
population in our study are those living in New York, who are primarily from the Dominican 
Republic and Puerto Rico by descent. The experiences we observed may differ from experiences 
of other Latinos with different ancestries and cultures.  
 
Practice Implications 
Many of the parents in our study understood CES as an investigation of many genes and 
were confused or relieved when no genetic cause was discovered after testing. This finding 
suggests that a more thorough explanation of the limitations and negative predictive value of 
testing needs to be conveyed to patients. Several patients seemed to be unaware of the possibility 
of an undetected genetic cause. Likewise, some parents misunderstood the implication of results 
which were de novo and had decided to forgo having additional children due to the risk of 
recurrence. Additional time is needed in sessions to convey the recurrence risk of de novo 
conditions and explain why there may be no family history.  
To address the anxiety of the waiting process, placing emphasis on the average 
turnaround time multiple times during the consult may be helpful. In addition, psychosocial 
counseling and support should be provided throughout the process, from pre-results to post-
results, to alleviate and explore any concerns parents may have. Providing a visual timeline that 
illustrates the process of CES that highlights the average wait time for return of results may also 
be supportive in generating realistic expectations. Some parents may find it helpful to connect 
with other parents who have had CES for their child. These parents may be a source of comfort 
or a more accurate resource during the wait time. If possible, Latino parents should be connected 
to each other, as the cultural and language aspects may provide an extra level of comfort.  
The Latino parents in our study did not differentiate between CES testing and previous 
genetic testing performed, suggesting that extensive information about the specific genetic tests 
may not be needed. Instead, it may be helpful to focus on the differences between a positive, 
negative, and VUS result, and what these results could mean for their family, their child, and 
their child’s medical management. This information may be further useful as in the form of 
written documentation, available to Latino parents in both Spanish and English regardless of 
what language they used in the results session. To support parents who are more comfortable 
speaking Spanish but lack confidence in speaking Spanish with providers, better educational 
materials can be developed to help them understand medical terminology in Spanish. In addition, 
acknowledging the role of faith and God in the parental experience of CES for their child may 
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Appendix VI. Interview Script 
Introduction 
● Tell me a little bit about why your child was referred to genetics or why you sought a 
genetics evaluation.  
● How and when did you first hear about exome sequencing? (Probe to find out when they 
first heard about it, who told them about it, or where they heard/read about it)  
● What were your first feelings or thoughts about whether this was something you wanted 
to consider for your child? What did you think this could add to your child’s care? What 
was your attitude towards genetic testing prior to getting the test done? 
● When making the decision about whether to do the genetic testing or not, did you seek 
input from other doctors or medical professionals beyond your genetics team?  Apart 
from medical professionals, did you ask anybody else their opinion about what you 
should do? (If yes) Who was that and why did you ask them for advice? What were the 
most important reasons why you decided to have the testing done?  
 
Pre-test/Consent Visit   
● After hearing about the test, what resources did you use to learn more?  
● Is there information you wish you had been given or understood before your child had the 
test? (If yes) What information is that? (probe about if they understood what positive, 
negative, VUS, and secondary finding results meant)  
● What were your hopes and expectations about the results for this test? 
● What were your reservations and doubts about this test? 
● Could we have done a better job discussing the testing during your visit?  How so? 
 
Language  
● What language did you use to speak with the doctor about the test? With the genetic 
counselor? 
● Was this the language you felt most comfortable speaking in about this topic? If no, what 
would you have preferred? 
● Did you use a translator/interpreter? If yes, who? Was the translator/interpreter on the 
phone, in person, a relative/friend at the appointment? How was this experience? 
● Did you have any difficulty finding other resources in your preferred language? 
 
Cost/Logistics  
• What made you decide to go to the genetics appointment? Did you think about not going 
or cancelling the appointment? Why? 
● Did you take a day off work to attend the appointment? Did you need childcare for your 
other children to attend the appointment? 
● What other arrangements, if any, did you make in order to attend the appointment? 
● How did you travel to the appointment? How did you pay for this transportation? 
● Do you remember if the entire cost of the testing was covered by your insurance or if you 
had to pay any part of the cost? (If had to pay some part of cost) How much did you have 
to pay?  
● Did you consider the cost of testing when deciding whether or not to have it?   
● Did you receive any assistance (from friends or family members) to help you to pay for 
the test?  
● How much would you have been able and willing to pay for the test if your insurance had 
not covered it?  
 
Understanding of results  
● Who told you the results for the first time?  The second time?   
● How did they communicate the results for each discussion (e.g., in face-to-face meeting 
with physician, by mail, by telephone)?  
● What language did the provider speak to tell you about the results? Was this your 
preference?  Was an interpreter used? Who? 
● Were you satisfied with how you learned the results? If not, how could this experience 
have been better? (by phone, in person, with someone else present?)  
● Did you feel the results were communicated in a way that enabled you to understand 
what they meant for your child? What would you have liked to have been done 
differently? 
● How do you feel about the results and why?  What have the positives and negatives been 
about having this result? 
● Are your feelings about the results what you expected they would be? If not, how are 
they different from what you expected?  
● Did you have any misunderstandings about the test results that you understand better 
now? 
● Did you look for any additional information about your child’s results online or 
somewhere else?  Where did you find information? Did you find that information 
helpful?  Not helpful? 
 
Social Impact   
● Did you share the results with your child’s other parent?  What was his/her response?  
Was it the same or different to your reaction? Was his/her reaction helpful or harmful?  In 
what way? 
● Who did you share your child’s results with? Did you share your test results with any 
other family members, friends, your child’s teachers? 
● Did you share your test results with your child’s therapists/doctors?  Which doctors? 
What was their reaction?  
● Have the results changed their perceptions/feelings about your child?  Have the test 
results changed your interactions with these people? Brought you closer? Weakened your 
relationship? Caused conflict?  
● Have any of your family members had genetic testing after learning about your child’s 
test results?  (inherited conditions only) 
● Are there family members you decided not to share the results with? (If yes) Why did you 
decide not to share the results with them?  
 
Life Impact   
● Have the results allowed you to join any specific support groups, research studies or meet 
other individuals with the same condition?  If so, what impact did that have? If not, what 
prevented you from finding/joining support groups? Were you unaware that these groups 
were available to you? Uninterested? Could not find a group in your preferred language?  
● Did anything negative happen to you in your job, insurance, or other areas of your life 
because of the results you received?  
 
Decision Satisfaction/Regret 
● Overall, how do you feel about your decision to have testing for your child?  
● Currently, what do you think has been the greatest benefit from the test?  
● If you were able to go back and choose the most optimal time for your child to have this 
test, when would you have liked to have it done? (probe to find out if they wanted it 
before a certain age or symptom onset)  
● What would you have changed about this experience?  
 
In Conclusion 
● What do you think has been the most difficult part of the entire process from when you 
first began thinking about having the test through getting the result?  
● Is there any kind of additional information or support that would have been helpful for 
you to have at any point in the process? (If yes) What kinds?  
● What advice would you give other parents contemplating this test for their child?  
● We are specifically trying to learn more about the experience of having this kind of 
testing in Latino families. How do you think your experience may have been different 
from people from other cultures or ethnicities?  
● Before we end, is there anything else you would like to say about the whole exome 
sequencing experience?  
 
Introduce that we will be sending them an electronic link/ paper survey with 8 questions 
$25 gift card. 
